Dupixent shows consistent, long-term efficacy in real-world

MIAMI BEACH, Florida — In two-real world studies, Dupixent treatment led to similar rapid and sustained improvements in patients with atopic dermatitis, according to a poster presentation at South Beach Symposium. Dupixent (dupilumab), a fully monoclonal antibody that blocks the shared receptor component for interleukin (IL)-4 and IL-13, is approved for the treatment of patients with

Related Keywords

Florida , United States , South Beach , Canada , New Jersey , Miami Beach , Sun Pharma , Kristen Dowd , Arcutis Biotherapeutics , Eli Lilly , Bygabrielle Capaldo , Taro Pharmaceutical Industries , Regeneron Pharmaceuticals , Amgen , Boehringer Ingelheim , Novartis , Pfizer , Psoriasis Treatment Center , South Beach Symposium , Menlo Therapeutics , Central New Jersey , Numeric Rating Scale ,